Immunai and Boehringer partner to identify T-cell targets
Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. The…
All articles by Salong Debbarma
Salong Debbarma
-
-
Ionis grants Recordati rights to zilganersen for Alexander disease
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to…
-
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a…
-
RQ Bio secures $115m to develop influenza antibody programme
UK-based RQ Bio has closed a £85.5m ($115m) Series A funding round to advance its long-acting antibody therapeutic programme RQB01,…
-
Boehringer and Combotope partner for cancer antibodies
Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer. The partnership…
-
Haisco and Nuvectis sign licensing deal for two drugs
Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based biotechnology company Nuvectis rights for two drug candidates in…
-
Genprex’s Reqorsa combo secures Canadian patent for lung cancer
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the…
-
Lilly and BioArctic sign deal to develop neurodegenerative therapy
Eli Lilly and Company has signed a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to develop a potential…
-
Sun Pharma to acquire Innovcare Lifesciences for $28.7m
Sun Pharmaceutical Industries has agreed to purchase India-based Innovcare Lifesciences in a deal valued at approximately Rs2.71bn ($28.7m). According to…
-
Japan approves Sanofi’s Sarclisa combo for MM treatment
Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for its subcutaneous (SC) formulation of Sarclisa (isatuximab)…